Abstract
Background Since there is still an unmet need for potent adjuvant strategies for renal cancer patients with high progression risk after surgery, several targeted therapies are currently evaluated in this setting. We analyzed whether inclusion criteria of contemporary trials (ARISER, ASSURE, SORCE, EVEREST, PROTECT, S-TRAC, ATLAS) correctly identify high-risk patients. Methods The study group comprised 8873 patients of the international CORONA-database after surgery for non-metastatic renal cancer without any adjuvant treatment. Patients were divided into potentially eligible high-risk and assumable low-risk patients who didn't meet inclusion criteria of contemporary adjuvant clinical trials. The ability of various inclusion criteria for disease-free survival (DFS) prediction was evaluated by Harrell's c-index. Results During a median follow-up of 53 months 15.2% of patients experienced recurrence (5-year-DFS 84%). By application of trial inclusion criteria, 24% (S-TRAC) to 47% (SORCE) of patients would have been eligible for enrollment. Actual recurrence rates of eligible patients ranged between 29% (SORCE) and 37% (S-TRAC) opposed to
Original language | English |
---|---|
Pages (from-to) | 744-750 |
Number of pages | 7 |
Journal | European Journal of Surgical Oncology |
Volume | 42 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 1 2016 |
Keywords
- Adjuvant therapy
- Disease recurrence
- Nephrectomy
- Phase-3-trials
- Renal cell cancer
- Targeted agents
ASJC Scopus subject areas
- Oncology
- Surgery